Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug
Was the FDA right to approve Aduhelm? What’s a fair price for a debatable drug? And what does this have to do with ’80s HIV activism?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this entire episode to the FDA’s polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer’s disease. First, we’ll break down what happened and why it’s such a big deal, and then we’ll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we’ll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.
